Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Which stock wins in a head-to-head matchup between these two big drugmakers?

Better Buy:  AbbVie vs.  Merck

Bristol-Myers

Eli Lilly

Pfizer

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Sees Rising Tide in Short Interest

Allergan

Amgen

Biogen

Celgene

Gilead Sciences

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

Spark Therapeutics

Roche Holding AG

Vertex Pharmaceuticals

Biotech companies exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

AbbVie has decided to potentially merge with Allergan.

I Increased My AbbVie Position, You Should As Well

Regeneron Pharmaceuticals

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more affordable.

Many Top Pharma & Biotechs Rise As Drug Price Disclosure Thrown Out

Iron Mountain

Macerich

Philip Morris

Williams

Some of the highest-yielding dividend stocks are actually bargains in the making. Here are five that have great prospects, cash flows, and profits to keep their high yields going.

The S&P 500’s Best Highest-Yielding Dividend Stocks

The AbbVie Allergan deal is being criticized for not being strategic and being more of the same.

AbbVie Allergan, A Boring But Prudent Deal

Enbridge

Lazard

Before I became an entrepreneur, I used to be a private banker. I was in charge of covering all financial planning aspects for wealthy clients.

3 Dividend Stocks Retirees Must Have in Their Portfolios

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

Bayer AG

GlaxoSmithKline

Johnson & Johnson

Novartis

Sanofi

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

AbbVie's stock has been hit hard by Humira's loss of exclusivity in Europe and the biotech's megamerger with Allergan.

Why AbbVie's Stock Sank in the First Half of 2019

Ford Motor Company

Seagate Technology Holdings PLC

These hefty dividend payouts can help you smooth out stock market wrinkles.

3 Dividend Stocks That Pay You More Than Exxon Does

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

McKesson

Walgreens

My investment management firm has a large position in the health care sector, and with AbbVie’s bid for Allergan earlier this week, it’s timely to review why we bought into this sector.

Here's Why Drug-Distribution and Pharmacy Stocks Are Bargains Now

Calithera Biosciences

Carnival

Denbury Resources

GigaMedia

TG Therapeutics

Insiders may sell their stock for many reasons but they only buy it if believe they will profit. Here are 7 stocks to buy along with insiders.

7 Stocks on Sale the Insiders Are Buying

AbbVie and Gilead shares have fallen considerably from their highs as serious concerns about future revenues have arisen.

AbbVie And Gilead - Two Different Strategies To Improve Growth

Immunomedics

Medicines

MGM Resorts

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: AbbVie, MGM and More

CenturyLink

Invesco

Macy's

Altria

Nielsen Hlds

Occidental Petroleum

AT&T

The names, the yields, and analysis on whether you can trust the dividends to be paid out for years.

The 10 Highest-Yielding Dividend Stocks in the S&P 500

Mirati Therapeutics

These three biotech stocks should be outstanding long-term growth vehicles.

Three Top Biotech Stocks to Buy Right Now

AbbVie's Allergan deal isn't as bad as some might think.

4 Reasons to Buy AbbVie Now That It's Acquiring Allergan

AbbVie has announced a plan to acquire Allergan for more than $60 billion. This transaction has been fully financed and is expected to close in early-2020.

AbbVie And Allergan - Take Advantage Of AbbVie's Share Price Drop

Ser yourself up for profits with a bullish call option.

This Pharmaceutical Company is Oversold and Starting to Recover

News for AbbVie Stock (ABBV)